

# Calendar of Events

## Radiation physics for clinical radiotherapy

5–9 September 1993

Leuven, Belgium

**Chairpersons:** H. Svensson (Umea)

**Faculty:** J. Dobbs (UK), G. Kantor (F), G. Leunens (B), B. Mijnheer (NL), A. Rijnders (B), P. Scalliet (B), J.E. Shaw (UK), H. Svensson (S), J. Van Dam (B)

**Session titles:** Basic radiation physics. Protocols for absorbed dose determination. Acquisition of clinical data for treatment planning. Conventional algorithms for 2D dose-calculations. CT as input for dose-planning. Advanced algorithms for 3D dose calculations. Accuracy requirements in radiation therapy. Target volume and target absorbed dose specification. Accelerators, principles. Quality control of teletherapy equipment. Dose distribution as a function of beam quality. Fractionation problems in dose planning. Fixation, filters and bolus. TBI, Medical aspects, treatment techniques.

**For further information contact:** ESTRO Secretariat, Department of Radiotherapy, U.H. St. Rafaël, Capucijnenvoer 35, 3000 Leuven, Belgium  
Tel: (32) 16 33.64.13  
Fax: (32) 16 33.64.28

## EORTC joint breast cancer meeting

15–17 September 1993

Nottingham, U.K.

**Speakers:** E. van der Schueren, R. Blamey, R. Rubens

**Session titles:** Opportunities for breast cancer research in Europe. Molecular genetics and breast cancer. Selection for breast conservation. Treatment of bone metastases. Do patients with advanced disease benefit from treatment?

**For further information contact:** Mrs Wendy Bartlam, Nottingham EORTC Joint Breast Cancer Meeting, Professional Unit of Surgery, City Hospital, Hucknall Road, Nottingham NG5 1PB, U.K.  
Tel: (44) 602 625707  
Fax: (44) 602 627765

## Cancer biology for clinicians—cancer update

24 September 1993

The Education and Conference Centre, The Royal Marsden Hospital, London, U.K.

**Chairpersons:** Robin Weiss, B. Gusterson, Martin Gore

**Session titles:** Recent advances in molecular biology  
New techniques in molecular biology.  
Molecular mechanisms of growth control.  
Molecular basis for familial cancer.  
Apoptosis.  
Potential treatment targets  
Mechanisms of tumour invasion. Tumour vasculature. Mechanisms of drug resistance.  
The biology of new treatments  
Antisense. Gene therapy. Retinoids.

**For further information contact:** The Education and Conference Centre, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, U.K.  
Tel: (44) 71 352 8171 Ext. 2921  
Fax: (44) 71 351 8172

## Basic clinical radiobiology

26–30 September 1993

Tours, France

**Chairpersons:** G.G. Steel (London), O. Le Floch (Tours)

**Faculty:** S. Bentzen (DK), S. Dische (UK), M.C. Joiner (UK), A. van der Kogel (NL), G.G. Steel (UK), F. Stewart (NL)

**Session titles:** Cell kinetics. Cell survival. Models of cell killing. Fractionation. L-Q formalism. Clinical radiobiology. Oxygen effect. Tumour radiobiology. Normal tissue damage. Radiosensitisers. Combined modality therapy. High-LET. Hyperthermia. Brachytherapy. Targeted radiotherapy. Prediction of response. Design of clinical trials.

**For further information contact:** ESTRO Secretariat, Department of Radiotherapy, U.H. St. Rafaël, Capucijnenvoer 35, 3000 Leuven, Belgium  
Tel: (32) 16 33.64.13  
Fax: (32) 16 33.64.28

## Head and neck tumours

30 September–2 October 1993

Vienna, Austria

**Chairpersons:** Snow (Amsterdam), Maciejewski (Gliwice)

**Faculty:** Maran (GB), Molinari (IT), Oloffson (NO), Soutar (GB), Zielinski (AT)

**Session titles:** Prognostic factors and staging. Pathology.

Oncologic surgery. Reconstructive surgery. Radiotherapy, chemotherapy, combined treatment, cancer immunology: basic concepts and applications. Precancerous lesions of the oral cavity and larynx. Management of the neck. Cancer of the oral cavity, oropharynx, nasopharynx, nose and sinuses, larynx, hypopharynx. Skin cancer. Neck metastases of unknown primary. Complications of head and neck surgery. Second primary cancer.

**For further information contact:** Mrs Dagmar Gollubics, The European School of Oncology, Vienna Office, c/o Arztekammer für Wien, Fortbildungsreferat, Weihburggasse 10-12, 1010 Vienna, Austria  
Tel: (43) 222-51501280  
Fax: (43) 51501240

## Breast imaging

1-3 October 1993

The Four Seasons Hotel, Toronto, Ontario, Canada

**Director:** Edward Kassel

**Chairman:** Walter Kucharczyk

Emphasis will be on Radiologic-Pathologic correlation. Interaction of conventional and advanced imaging modalities will be discussed. Panel discussion will be held on October 3.

**For further information contact:** Dawne Ryals, Ryals and Associates, P.O. Box 1925, Roswell, Georgia 30077-1925, U.S.A.

Tel: (404) 641-9773

Fax: (404) 552-9859

Sponsored by The Department of Radiology, University of Toronto

## Current concepts of magnetic resonance

3-6 October 1993

Ritz-Carlton Resort Hotel, Laguna Niguel, California

**Director:** Norbert J. Pelc

The course is designed to address the need for individuals with an interest in an expanded understanding of the fundamental techniques and clinical application of MRI.

**For further information contact:** Dawne Ryals, Ryals and Associates, P.O. Box 1925, Roswell, Georgia 30077-1925, U.S.A.

Tel: (404) 641-9773

Fax: (404) 552-9859

Sponsored by the Radiology Departments of Stanford University Medical Center and Duke University Medical Center

## Breast cancer

4-7 October 1993

Orta San Giulio, Italy

**Chairpersons:** U. Veronesi (Milan), M. Osborne (New York)

**Faculty:** Bonadonna (IT), Boyle (IT), Costa (IT), Gianni (IT), Goldhirsch (CH), Holland (NL), Petit (FR), Serin (FR)

**CME Advisor:** M.P. Moore (New York)

**Discussion Leader:** Sacchini (IT)

**Session titles:** Epidemiology and risk factors.

Chemoprevention. Screening. Diagnosis.

Follow-up management. Non-palpable lesions.

Biology and pathology. Local spread: multifocality; intraductal component.

Prognostic factors and clinical relevance.

Treatment options. Surgical management.

Premalignant lesions and *in situ* breast cancer: biological behaviour and management options.

Conservative treatments: options and update of clinical trials. Risk factors and management of recurrences after conservative treatment.

Management of axillary lymph nodes.

Expanding the indications for breast conservation with primary chemotherapy.

Adjuvant and palliative radiotherapy. Adjuvant treatments: indication in node-negative patients.

Treatment of advanced disease: high dose chemotherapy, bone marrow transplantation and growth factors. Breast reconstruction.

**For further information contact:** European School of Oncology, Via G. Venezian 18, 20133 Milan, Italy  
Tel: (39 2) 70635923-2360410-2364283

Fax: (39 2) 2664662

This course, jointly organised with Memorial Sloan-Kettering Cancer Center, New York, is accredited for Continuing Medical Education in CATEGORY 1. In collaboration with the European Society of Mastology

## The role of radiotherapy in the management of cancer

17-21 October 1993

Prague, Czech Republic

**Chairpersons:** T. Landberg (Malmö), Z. Chodounsky (Prague)

**Faculty:** N. Daly (F), J.W. Leer (NL), J. Overgaard (DK), A. Timothy (UK)

**Session titles:** Cancer panorama in Europe. Cancer epidemiology. General principles in radiation oncology. General overview of radiobiology. Head and neck cancer. Lung cancer. CNS tumours. Breast cancer. Gynaecology. Urological cancers. Gastro-intestinal cancers. Lymphomas. Palliative radiotherapy. Treatment of pain. Emergency radiotherapy. Paediatric tumours.

**For further information contact:** ESTRO Secretariat, Dept. of

Radiotherapy, U.H. St. Rafaël Capucijnenvoer 35, 3000 Leuven, Belgium.  
Tel: (32) 16 33 64 13  
Fax: (32) 16 33 64 28

## Palliative care of cancer patients

Jointly organised with Danish Cancer Society  
17–21 October 1993

Copenhagen, Denmark

**Chairpersons:** O.S. Nielsen (Aarhus), V. Ventafridda (Milan)

**Faculty:** Doyle (GB), Hanks (GB), Maguire (GB), Poulain (FR), Webber (GB)

**Session titles:** Philosophy of palliative care. Teamwork.

General principles of pain control and assessment. Strategy for drug treatment of pain. Adjuvant analgesics and management of neuropathic pain. Non-drug treatment of pain. Adjusting to a poor prognosis. Nausea and vomiting. Bone metastasis. Spinal cord compression. Dyspnoea and superior vena caval obstruction. Terminal care and hospice. Effective communication. Anxiety and depression. Dysphagia. Gastro-intestinal obstruction. Delirium. Corticosteroids. Brain metastases. Quality of life. An oncologist's pragmatic view. Ethics. Education and training. Psychological, social and spiritual aspects. Role of the nurse: nursing issues. Breaking bad news. Truth telling. Care of the family. Palliative care services. Implementation and monitoring of palliative care

**For further information contact:** The European School of Oncology, Copenhagen Office, c/o Danish Cancer Society, Rosenvaengets Hovedvej 35, DK-2100 Copenhagen, Denmark  
Tel: (45) 312-68866  
Fax: (45) 312-264560  
Jointly organised with the Danish Cancer Society

## Lymphomas

Jointly organised with the University of Athens  
18–22 October 1993

Corfu, Greece

**Chairpersons:** G. Pangalis (Athens), A. Polliack (Jerusalem)

**Faculty:** Boussiotis (US), Canellos (US), Coiffier (FR), Diehl (DE), Goldstone (GB), Kittas (GR), Kosmidis (GR), Montserrat (ES), Panaylotidis (GB), Papadimitriou (GR), Papavassiliou (GR), Pavlidis (GR), Sikora (GB)

**Session titles:** Diagnosis and classification. Molecular genetics and oncogenes. Lymphokines. Staging, prognostic factors. Hodgkin's disease. Non-Hodgkin lymphomas. Radiotherapy. Primary extranodal lymphomas. T-cell lymphomas. Lymphomas in childhood, in immunocompromised hosts. New therapeutic strategies; BMT. Long-term complications of therapy. Potentially malignant lymphomas. Leukaemic phase.

**For further information contact:** Scientific Secretariat, The European School of Oncology, G. Assimakopoulos, Karneadou, 3 10675 Kolonaki, Athens, Greece  
Tel: (30) 1-7231693  
Fax: (30) 1-7250072

## Cancer clinical trials

18–22 October 1993

Brussels, Belgium

**Chairpersons:** J.G. McVie (London), M. Baum (London), D. Riley (London), C. Molin (Stockholm)

**Programme Coordinator:** K. Vantongelen (Leuven)

**Faculty:** Blackledge (GB), Castiglione (CH), Dalesio (NL), Dubbelman (NL), Fallowfield (GB), Franklin (NL), Gall (NL), Hill (FR), Houghton (GB), Marsoni (IT), Meunier (BE), Parmar (GB), Pavlidis (GR), Sylvester (BE), Tagnon (BE), Van der Schueren (BE), Van Glabbeke (BE), Van Oosterom (BE), Webb (GB)

**Session titles:** The need for science in medicine. Clinical trials versus standard treatment. Multidisciplinary approach. How to translate an interesting question into a clinical trial. The role of statistics in clinical trials. Protocol review. Ethical issues; legal constraints, informed consent, privacy of data, doctor/patient relationship. EORTC Data Centre visit. Role of the data centre. Design of clinical trials: design, sample size, randomisation, stratification. Data analysis: basic principles, analysis techniques, models, prognostic factors, interim analysis, early stopping rules. Nurses' role and contribution in observation, interpretation and recording of adverse effects. Patient and family information and education. Response evaluation, reporting toxicity, computers and organisation, audits. Reporting results. Interpretation of published results. Meta-analysis. Quality-of-life assessments. Cost evaluation of clinical trials. Implementation of good clinical practice. Impact of trial results on clinical practice. Priorities in cancer clinical trials.

**For further information contact:** Mrs Martine Verbanck, The European School of Oncology, Brussels Office, Avenue Mounier 83, 1200 Brussels, Belgium  
Tel: (32 2) 7724621  
Fax: (32 2) 7726233

Organised by ESO and EORTC in collaboration with BODMA, CKVO, CRC, DUMD, FNCLCC, MRC and SAKK

## Growth factors: from basic science to the clinic

19–21 October 1993

San Servolo Island, Venice, Italy

**Chairperson:** M. Sporn (Bethesda)

**Faculty:** Brandl (IT), Dexter (GB), Heldin (SE), Lefer (US), Unsicker (DE), Wahl (US)

**Session titles:** Hematopoiesis, Cardiovascular disease,

neurological disease, cancer, inflammatory disease, growth factors and bone.

This seminar will consider accomplishments and possibilities regarding the use of peptide growth factors (cytokines), as well as their antagonists, for treatment of human disease. In five major areas, the relevant scientific basis (tissue, cell and molecular biology) will be presented in detail, followed by consideration of practical clinical applications. Among the cytokines that will be discussed in this Seminar are: EGF/TGF- $\alpha$ , PDGF, FGF, TGF- $\beta$ , the interleukins, hematopoietic colony-stimulating factors, interferons, tumour necrosis factors, bombesin, nerve growth factor and related neurotrophic peptides. Development of selected antagonists of the above cytokines will also be considered.

**For further information contact:** European School of Oncology, Via G. Venezian 18, 20133 Milan, Italy  
Tel: (39 2) 70635923-2360410-2364283  
Fax: (39 2) 2664662

## **Children and cancer: psychological support and social assistance**

21–23 October 1993

SWITEL, Antwerp, Belgium

**Chairpersons:** N. Alby, Y. Banoit, G. Cornu, J. Foubert, J. Appelboom, J.M. Chantraine

**Session titles:** The child face-to-face with cancer: the problems, the support. The child, life and death. The healing process.

**For further information contact:** Paul Matthys, Zaterdagplein 13, 1000 Brussels, Belgium  
Tel: (32) 2 219 4820  
Fax: (32) 2 218 5327

## **Good clinical practice**

25–29 October 1993

Vienna, Austria

**Chairpersons:** Friedman (Bethesda), M. Aapro (Geneva)  
**Faculty:** Kerpel-Fronius (HU)

**Session titles:** Preclinical development: acquisition, testing and selection of agents. Guidelines for clinical studies—pharmacology/pharmacokinetics, toxicology, pharmaceutical. Phase II studies: design, endpoints, and number of patients, tumour types, studies and schedules. Phase II studies: design, endpoints, and number of patients, tumour types, studies and schedules. Cytotoxic, biological, mdr-reversing/chemoprotector/chemosensitiser/radiosensitiser/radioprotector agents. Regulatory issues—INDS, responsibility of investigators, informed consent, IRBS, monitoring. Endpoints for drug approval. FDA, recent examples of FDA approvals. The pharmaceutical company perspective. Making an effective investigational agent more widely available through TRC, Group C and/or special exception. FDA

perspective in all these issues.

**For further information contact:** Mrs Dagmar Gollubics, The European School of Oncology, Vienna Office, c/o Arztekammer für Wien, Fortbildungsreferat, Weihburggasse 10–12, 1010 Vienna, Austria

Tel: (43) 222-51501280

Fax: (43) 222-51501240

## **Interactions of cancer susceptibility and environmental carcinogens**

9–13 November 1993

International Agency for Research on Cancer, Lyon, France

**Chairpersons:** F.P. Li (Dana Farber Cancer Center, Boston, Massachusetts, U.S.A.), R. Montesano (International Agency for Research on Cancer, Lyon, France)

The meeting will be attended by a maximum of 25 speakers and 150 participants.

**The scientific topics to be covered:** Mechanisms and experimental models of genetic susceptibility, new experimental models using genetically defined systems including biomarkers, transgenerational effects, genomic imprinting, recent advances in human cancer (e.g. ataxia, ultraviolet radiation), non-genotoxic agents, human genetic susceptibility.

All accepted participants will be eligible to present one poster of their own work. The meeting report will be published in an international journal.

**For further information and registration/abstract forms contact:** The Unit of Education and Training, International Agency for Research on Cancer, 150, Cours Albert Thomas, F-69373 Lyon, Cédex 08, France

Jointly organised by the International Agency for Research on Cancer and the American Association for Cancer Research, Inc.

## **Gynaecological and breast tumours: diagnostic and prognostic factors**

11–12 November 1993

San Servolo Island, Venice, Italy

**Chairpersons:** A. Weger (Stockholm), P. van Diest (Amsterdam), J. Lindholm (Stockholm)

**Faculty:** Einhorn (SE), Montironi (IT), Rilke (IT), Vermorken (NL)

**Session titles:** Gynaecology and breast oncology and pathology. Molecular and immunological tumour pathology. Flow and image cytometry for quantification of DNA, proliferation, proteins and oncogene products. Morphometry and stereology. Statistics. Cooperation between disciplines. Applications of quantitative techniques in breast cancer. Applications of quantitative techniques in gynaecological tumours.

**For further information contact:** European School of Oncology, Via G. Venezian 18, 20133 Milan, Italy

Tel: (39 2) 70635923-2360410-2364283  
Fax: (39 2) 2664662

## Lung cancer

12–13 November 1993

Vienna, Austria

**Chairpersons:** Neumann (Vienna), N. Van Zandwijk (Amsterdam)

**Faculty:** Ardizzone (IT), Dalesio (NL), Giaccone (IT), Gregor (GB), Micksche (AT), Mooi (NL), Pastorino (IT), Postmus (NL), Rocmans (BE), Schirren (DE)

**Session titles:** Histopathology, epidemiology, aetiology, prevention. Biology, screening and early diagnosis. Staging systems. Pre and post-operative anti-neoplastic treatment: radiotherapy, chemotherapy. Radiotherapy and chemotherapy of unresectable NSCLC. Small cell carcinoma: chemotherapy, radiotherapy, surgery. Primary lung tumour in mediastinum. Extra-pulmonary metastases. Lung function studies. Surgery and radiotherapy, technical aspects. Complications secondary to primary tumour. Complications secondary to treatment. Mediastinal tumours, mesothelioma, surgery of metastases.

**For further information contact:** Mrs Dagmar Gollubics, The European School of Oncology, Vienna Office, c/o Arztekammer für Wien, Fortbildungsreferat, Weihburggasse 10–12, 1010 Vienna, Austria  
Tel: (43) 222-51501280  
Fax: (43) 222-51501240

## Soft tissue tumours—cancer update

26 November 1993

The Education and Conference Centre, The Royal Marsden Hospital, London, U.K.

**Chairpersons:** C. Harmer, C. Fisher

**Session titles:** Diagnosis  
Current concepts in pathology and grading.  
Molecular diagnostics and genetics.  
Cytogenetics and *in situ* hybridisation.  
Presentation, diagnosis and initial assessment.  
Imaging strategies.  
Management of local disease  
Surgical management. Conservation and reconstruction in sarcoma surgery.  
Radiotherapy.  
Management of metastatic disease

New approaches to chemotherapy. Surgery of pulmonary metastasis.

**For further information contact:** The Education and Conference Centre, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, U.K.

Tel: (44) 71 352 8171 Ext. 2921

Fax: (44) 71 351 8172

## Cancer registration, creation and use of data

3–6 December 1993

Copenhagen, Denmark

**Chairperson:** H. Storm (DK)

**Faculty:** Adami (SE), Berrino (IT), Boyle (IT), Hakulinen (FI), Langmark (NO), Muir (FR), Overgaard (DK), Teppo (FI), Tulinius (IS)

**Session titles:** Purpose and use of cancer registration: international data sources, use of data, sources. Planning a cancer registry. Confidentiality and legal aspects. Cancer diseases: pathology, clinic, diagnostic radiotherapy. Quality control. Analysis and reporting. Survival and care.

**For further information contact:** The European School of Oncology, Copenhagen Office, c/o Danish Cancer Society, Rosenvaengets Hovedvej 35, DK-2100 Copenhagen, Denmark  
Tel: (45) 312-68866  
Fax: (45) 312-264560

## First Educational Convention of The European School of Oncology

16–18 June 1994

Palais des Congrès, Paris, France

Competitive submission of abstracts for 10 sessions on: Oncogenes, Suppressor genes and growth factors. New drug development. Biological response modifiers. Epidemiology. Diagnosis, treatment and prognostic factors in: Breast cancer, leukaemias, colorectal cancer, lymphomas, lung cancer, ovarian cancer.  
Deadline for abstracts: 31 December 1993

**For further information contact:** Dr Claudia Ferrari, Bedin Centonze Associées, 12 rue Berteaux Dumas, 92200 Neuilly, France  
Tel: (33) 1 46971971  
Fax: (33) 1 47722852  
Made possible by an educational grant from Farmitalia Carlo Erba